Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.

Humans Cause of Death Hematopoietic Stem Cell Transplantation / methods Communicable Diseases / etiology Lymphoma Chronic Disease Leukemia, Myeloid, Acute / etiology Retrospective Studies

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
08 2023

Historique:

received: 20 12 2022

accepted: 19 04 2023

revised: 15 04 2023

medline: 7 8 2023

pubmed: 7 5 2023

entrez: 6 5 2023

Statut: ppublish

Résumé

We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in two time periods, 1980-2001 (cohort-1) and 2002-2015 (cohort-2). All patients with HCT for lymphoma, plasma cell disorders, chronic leukemia (except CML), myelodysplastic/myeloproliferative disorders, registered in the EBMT-ProMISe-database were included (n = 232,618) (COD-2 study). Results were compared to those in the ALL/AML/CML COD-1 study. Mortality from bacterial, viral, fungal, and parasitic infections decreased in very early, early and intermediate phases. In the late phase, mortality from bacterial infections increased, while mortality from fungal, viral, or unknown infectious etiology did not change. This pattern was similar for allo- and auto-HCT in COD-1 and COD-2 studies, with a distinct and constant lower incidence of all types of infections at all phases, after auto-HCT. In conclusion, infections were the main cause of death before day +100, followed by relapse. Mortality from infectious deaths significantly decreased, except late phase. Post-transplant mortality has significantly decreased in all phases, from all causes after auto-HCT; it has decreased in all phases after allo-HCT except late phase.

Identifiants

DOI: 10.1038/s41409-023-01998-2 PMID: 37149673

pubmed: 37149673

doi: 10.1038/s41409-023-01998-2

pii: 10.1038/s41409-023-01998-2

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

881-892

Informations de copyright

Références

Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S. et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transpl. 2020;55:126–36. https://doi.org/10.1038/s41409-019-0624-z .

doi: 10.1038/s41409-019-0624-z

Holmqvist AS, Chen Y, Wu J, Battles K, Francisco L, Hageman L. et al. Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia. Biol Blood Marrow Transpl. 2019;25:749–55. https://doi.org/10.1016/j.bbmt.2018.12.063 .

doi: 10.1016/j.bbmt.2018.12.063

Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J. et al. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:362–8. https://doi.org/10.1016/j.bbmt.2018.09.031 .

doi: 10.1016/j.bbmt.2018.09.031

Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P. et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transpl. 2005;36:757–69. https://doi.org/10.1038/sj.bmt.1705140 .

doi: 10.1038/sj.bmt.1705140

Hahn T, Sucheston-Campbell LE, Preus L, Zhu X, Hansen JA, Martin PJ. et al. Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2015;21:1679–86. https://doi.org/10.1016/j.bbmt.2015.05.019 .

doi: 10.1016/j.bbmt.2015.05.019

Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM. et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transpl. 2007;13:1469–76. https://doi.org/10.1016/j.bbmt.2007.08.047 .

doi: 10.1016/j.bbmt.2007.08.047

Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R. et al. Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. Leukemia. 2017;31:1752–9. https://doi.org/10.1038/leu.2017.79 .

doi: 10.1038/leu.2017.79 pubmed: 28270691

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.

doi: 10.1097/00007890-197410000-00001 pubmed: 4153799

Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, et al. Economics and Outcome After Hematopoietic StemCell Transplantation: A Retrospective Cohort Study. EBioMedicine. 2015;2:2101–9.

doi: 10.1016/j.ebiom.2015.11.021 pubmed: 26844291 pmcid: 4703735

Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2013;48:S1–37. https://doi.org/10.1038/bmt.2012.282 .

doi: 10.1038/bmt.2012.282

Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer-Verlag; 2003.

Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L. et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–100. https://doi.org/10.1016/S2352-3026(15)00028-9 .

doi: 10.1016/S2352-3026(15)00028-9 pubmed: 26687803

Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S. et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107:1045–53. https://doi.org/10.3324/haematol.2021.279189 .

doi: 10.3324/haematol.2021.279189 pubmed: 34382386

Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl J Med. 2010;363:2091–101. https://doi.org/10.1056/NEJMoa1004383 .

doi: 10.1056/NEJMoa1004383 pubmed: 21105791 pmcid: 3017343

Meyers JD, Bowden RA, Counts GW. Infectious complications of marrow transplant: risk factors for infection. Prog Clin Biol Res. 1989;309:357–66.

pubmed: 2675104

Styczynski J, Piekarska A, Zaucha-Prażmo A, Zaucha JM, Zając-Spychała O, Wróbel T. et al. Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations. Acta Haematol Pol. 2021;52:528–42. https://doi.org/10.5603/AHP.a2021.0097 .

doi: 10.5603/AHP.a2021.0097

Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P. et al. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica. 2014;99:908–15. https://doi.org/10.3324/haematol.2013.096461 .

doi: 10.3324/haematol.2013.096461 pubmed: 24488562 pmcid: 4008105

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF. et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N. Engl J Med. 2017;377:2433–44. https://doi.org/10.1056/NEJMoa1706640 .

doi: 10.1056/NEJMoa1706640 pubmed: 29211658